GLP-1 medications, such as semaglutide and tirzepatide, were originally designed for diabetes, but their impact on weight, inflammation, and metabolic health has fundamentally changed how we approach liver disease. Excess weight, insulin resistance, and metabolic dysfunction are now the leading drivers of liver injury worldwide, and GLP-1s directly target these root causes. Patients taking these...